Marlies Wijsenbeek
YOU?
Author Swipe
View article: Healthcare Professionals’ Perspectives on Implementation of Home Monitoring in Individuals with Pulmonary Fibrosis
Healthcare Professionals’ Perspectives on Implementation of Home Monitoring in Individuals with Pulmonary Fibrosis Open
Introduction Home monitoring of physical parameters, symptoms, and quality of life by individuals with pulmonary fibrosis (PF) could overcome gaps in clinical care by early detecting disease deterioration, guiding patient management, and i…
View article: Osteoprotegerin Is Elevated in Pulmonary Fibrosis and Associates with Idiopathic Pulmonary Fibrosis Progression: A Pilot Study
Osteoprotegerin Is Elevated in Pulmonary Fibrosis and Associates with Idiopathic Pulmonary Fibrosis Progression: A Pilot Study Open
Introduction: Osteoprotegerin (OPG), a decoy receptor for receptor activator of NF-κB ligand (RANKL), serves as a biomarker for liver fibrosis severity. Our recent findings show OPG production in fibrotic lung tissue, though its specific c…
View article: Innovating care for people with sarcoidosis using a machine learning-driven approach
Innovating care for people with sarcoidosis using a machine learning-driven approach Open
A major part of living with sarcoidosis takes place outside the view of the hospital, but this part often remains invisible. MLD is an innovative approach, providing a comprehensive overview of patients' perspectives on health and care. In…
View article: Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement Open
Background: There is growing interest in identifying early stages of interstitial lung disease (ILD) to improve patient outcomes. This document reviews updated evidence on interstitial lung abnormalities (ILAs); provides suggestions…
View article: Correction: The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis
Correction: The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis Open
View article: Cough and dyspnea management in pulmonary fibrosis
Cough and dyspnea management in pulmonary fibrosis Open
Purpose of the review Pulmonary fibrosis (PF) is characterized by relentless scarring of the lungs, declining lung function, and increasing symptom burden. In PF, dyspnea and cough are the most common symptoms, severely impacting quality o…
View article: Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti‐Fibrotic Treatment: Real‐World Data From the Dutch National Registry
Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti‐Fibrotic Treatment: Real‐World Data From the Dutch National Registry Open
Background and Objective Real‐world data on lung function course of patients with progressive pulmonary fibrosis (PPF) treated with anti‐fibrotic medication are limited. We evaluated forced vital capacity (FVC) decline in patients with PPF…
View article: Online home spirometry in national pulmonary fibrosis care: insights from daily practice
Online home spirometry in national pulmonary fibrosis care: insights from daily practice Open
Background Monitoring lung function course in patients with pulmonary fibrosis is crucial to guide treatment decisions. Online home spirometry holds great potential for close monitoring and improving care access in times of pressured healt…
View article: European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD)
European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD) Open
Background and aims Predicting progression and prognosis in Interstitial Lung Diseases (ILD), especially Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), remains a challenge. Integrating patient-centered measur…
View article: Cough monitoring systems in adults with chronic respiratory diseases: a systematic review
Cough monitoring systems in adults with chronic respiratory diseases: a systematic review Open
Background The role of objective cough monitoring systems for assessments in adults with chronic respiratory diseases (CRDs) is unclear. This systematic review aimed to synthesise current literature on frequency of use and characteristics …
View article: Design of Resolve Lung, a Multinational Phase 2, Randomized, Placebo-Controlled Trial of the Anti-Gm-Csf Monoclonal Antibody Namilumab in Patients with Chronic Pulmonary Sarcoidosis
Design of Resolve Lung, a Multinational Phase 2, Randomized, Placebo-Controlled Trial of the Anti-Gm-Csf Monoclonal Antibody Namilumab in Patients with Chronic Pulmonary Sarcoidosis Open
View article: Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement
Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement Open
Background: There is increasing interest in the use of home-based monitoring in people with chronic lung diseases to improve access to care, support patient self-management, and facilitate the collection of information for clinical …
View article: Patient-centered care in pulmonary fibrosis: access, anticipate, and act
Patient-centered care in pulmonary fibrosis: access, anticipate, and act Open
Comprehensive care integrates individual patient needs and is highly valued for patients with pulmonary fibrosis (PF). The importance of a patient-centered care approach is rooted in the unpredictable progressiveness of the disease course …
View article: A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease
A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease Open
View article: Breathing techniques to reduce symptoms in people with serious respiratory illness: a systematic review
Breathing techniques to reduce symptoms in people with serious respiratory illness: a systematic review Open
Background In adults with serious respiratory illness, breathlessness is prevalent and associated with reduced health-related quality of life. The aim of this review was to assess the impact of breathing techniques on breathlessness in adu…
View article: Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis
Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis Open
Background People living with serious respiratory illness experience a high burden of distressing symptoms. Although opioids are prescribed for symptom management, they generate adverse events, and their benefits are unclear. Methods We ex…
View article: Is YouTube a sufficient source of information on Sarcoidosis?
Is YouTube a sufficient source of information on Sarcoidosis? Open
Background The internet is a common source of health information for patients and caregivers. To date, content and information quality of YouTube videos on sarcoidosis has not been studied. The aim of our study was to investigate the conte…
View article: Worsening dyspnoea as a predictor of progression of pulmonary fibrosis
Worsening dyspnoea as a predictor of progression of pulmonary fibrosis Open
Among patients with progressive pulmonary fibrosis, worse dyspnoea at baseline and a worsening of dyspnoea over 24 weeks were associated with an increased risk of disease progression https://bit.ly/3APvQL7
View article: The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis
The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis Open
Background Cough remains a persistent symptom in patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). To inform future research, treatment and care models, we conducted the first systematic synthes…
View article: Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis
Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis Open
Nintedanib dose was significantly associated with FVC loss. However, no significant relationship between nintedanib exposure and the occurrence of DLTs was found in this real-world population, and no therapeutic window could be established…
View article: Objective measurement of cough in pulmonary fibrosis: a cohort study – ImpaCT
Objective measurement of cough in pulmonary fibrosis: a cohort study – ImpaCT Open
Using both objective cough monitoring and patient-reported outcomes measures, this study describes the burden of cough for patients with non-IPF pulmonary fibrosis https://bit.ly/3wFm0th.
View article: ``It Is a Moving Process": Understanding the Evolution of Explainability Needs of Clinicians in Pulmonary Medicine
``It Is a Moving Process": Understanding the Evolution of Explainability Needs of Clinicians in Pulmonary Medicine Open
Clinicians increasingly pay attention to Artificial Intelligence (AI) to improve the quality and timeliness of their services. There are converging opinions on the need for Explainable AI (XAI) in healthcare. However, prior work considers …
View article: European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness Open
Respiratory symptoms are ubiquitous and impair health-related quality of life in people with respiratory disease. This European Respiratory Society (ERS) task force aimed to provide recommendations for symptomatic treatment in people with …
View article: Increased proportions of circulating PD-1+ CD4+ memory T cells and PD-1+ regulatory T cells associate with good response to prednisone in pulmonary sarcoidosis
Increased proportions of circulating PD-1+ CD4+ memory T cells and PD-1+ regulatory T cells associate with good response to prednisone in pulmonary sarcoidosis Open
Background The treatment response to corticosteroids in patients with sarcoidosis is highly variable. CD4 + T cells are central in sarcoid pathogenesis and their phenotype in peripheral blood (PB) associates with disease course. We hypothe…
View article: Classifying Interstitial Lung Disease: Omics Are in the Air
Classifying Interstitial Lung Disease: Omics Are in the Air Open
"Classifying Interstitial Lung Disease: Omics Are in the Air." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
View article: 246P Detection of drug-induced interstitial lung disease caused by cancer treatment using electronic nose exhaled breath analysis
246P Detection of drug-induced interstitial lung disease caused by cancer treatment using electronic nose exhaled breath analysis Open
Many cancer treatments are associated with potentially life-threatening drug-induced interstitial lung disease (DIILD), also known as drug-related pneumonitis. Chest CT scan is used for screening and monitoring DIILD in patients on high-ri…
View article: Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial
Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial Open
View article: Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: A systematic review
Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: A systematic review Open
View article: Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency Open
Background: Idiopathic pulmonary fibrosis (IPF) carries significant mortality and unpredictable progression, with limited therapeutic options. Designing trials with patient-meaningful endpoints, enhancing the reliability and interpr…
View article: An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis Open
Background There is no standard definition of respiratory-related hospitalisation, a common end-point in idiopathic pulmonary fibrosis (IPF) clinical trials. As diverse aetiologies and complicating comorbidities can present similarly, exte…